Kolexia
Hollebecque Antoine Oncologie médicale
Hollebecque Antoine
Oncologie médicale
Gustave-Roussy
Villejuif, France
499 Activités
1.2 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Cholangiocarcinome Tumeurs du poumon Tumeurs colorectales Carcinome pulmonaire non à petites cellules Tumeurs du pancréas Tumeurs des voies biliaires Lymphomes Adénocarcinome

Collaborateurs

Voir plus
Soria Jean-Charles
Soria Jean-Charles
Gustave-Roussy, Villejuif, France
Massard Christophe
Massard Christophe
Gustave-Roussy, Villejuif, France
Gazzah Anas
Gazzah Anas
Gustave-Roussy, Villejuif, France
Baldini Capucine
Baldini Capucine
Gustave-Roussy, Villejuif, France

Industries

Voir plus
Incyte
12 collaboration(s)
Dernière en 2023
Servier
12 collaboration(s)
Dernière en 2023
CanceroDigest
6 collaboration(s)
Dernière en 2023
BMS
4 collaboration(s)
Dernière en 2020

Dernières activités

Voir plus
A Study of SGN-B6A in Advanced Solid Tumors: A Phase 1 Study of SGN-B6A in Advanced Solid Tumors
Essai Clinique (Seagen)   15 mars 2024
PACT: A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT)
Essai Clinique (Lilly)   14 mars 2024
Codon-specific KRAS mutations predict survival in advanced pancreatic cancer
ESMO Gastrointestinal Oncology   01 mars 2024
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors: Phase 1/2 Dose Escalation and Cohort Expansion Study Evaluating MCLA-158 (Petosemtamab) as Single Agent or in Combination in Advanced Solid Tumors
Essai Clinique (Merus N.V.)   01 mars 2024
Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients.
NPJ precision oncology   26 février 2024
Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study.
BMC cancer   26 février 2024
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100): A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Sotorasib (AMG 510) Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and Sotorasib (AMG 510) Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreaK 100)
Essai Clinique (Amgen)   22 février 2024
A Study of TAS-120 in Patients With Advanced Solid Tumors: Phase 1/2 Study of TAS-120 in Patients With Advanced Solid Tumors Harboring FGF/FGFR Aberrations
Essai Clinique (Taiho Oncology, Inc.)   20 février 2024
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring gene fusions.
Future oncology (London, England)   13 février 2024
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors: A Phase 1/2 Study of BMS-986449 Alone and in Combination With Nivolumab in Participants With Advanced Solid Tumors
Essai Clinique (BMS)   09 février 2024